Hearing-Aid Market Growth Forecast Rises to 3-5%

Hearing-care providers and suppliers should expect stronger demand as AI-enabled devices gain share across the sector.

Updated on Nov. 12, 2026 in Healthcare

A small matte beige hearing-aid-shaped object sits on a clean pale grey bench in soft window light with a calm, empty lab background.
Sonova raised its fiscal 2027 sales and profit guidance on November 12, 2026, now forecasting 3% to 5% global hearing-aid market growth on share gains and AI-powered Phonak EON demand. AI Illustration. Upload story photo >

Swiss hearing-aid maker Sonova raised its fiscal 2027 sales and core profit guidance on November 12, 2026, citing market-share gains and strong uptake of new products. The upgrade matters to operators across the hearing-care supply chain because it signals a stronger-than-previously-expected global market.

Why it matters

Sonova, the world's largest hearing-aid maker, lifted its outlook after gains in market share and solid uptake of its new AI-powered Phonak EON platform. The company also now expects the global hearing-aid market to grow 3% to 5% this year, up from 2% to 4%, which suggests demand momentum beyond a single firm.

Sonova's sales guidance rose to 6% to 8% in local currency from 5% to 8%, and core operating profit guidance rose to 10% to 13% from 7% to 10%. Asia-Pacific sales grew 11.4% to 186.9 million francs in the first half, with mid-teens hearing-instrument growth in Australia, China and Japan.

The players

Sonova

Swiss hearing-aid maker and the world's largest producer of hearing aids, selling through its Phonak brand and related hearing-care products.

Demant

Danish hearing-care company and a major rival to Sonova, which raised its own full-year guidance twice this year.

The details

Sonova attributes the raised outlook to gains in market share and solid uptake of new products, particularly its AI-powered Phonak EON platform. CEO Eric Bernard said EON is already contributing above the company's expectations. The rollout of the platform across markets has supported growth and share gains, and the company's guidance now reflects that momentum.

Timeline

  1. October: rival Demant raised its full-year guidance for the second time this year.

  2. First half of fiscal year (through September 2026): Sonova Asia-Pacific sales rose 11.4%.

  3. November 12, 2026: Sonova raised its fiscal 2027 sales and profit guidance.

  4. Year through March 2027: the fiscal 2027 guidance period.

Market Landscape

The raised outlook comes as rival Demant also lifted its full-year guidance twice this year, pointing to a sector-wide upswing rather than a company-specific bump. Sonova's Phonak EON platform is now the central reference point for its growth story as competitors race to bring AI-enabled hearing products to market.

Operators in hearing-care retail, audiology, and related supply should factor in a stronger market outlook and rising competition for new-product adoption. Procurement and sales teams may find that demand for AI-enabled devices is growing faster than the broader market, which argues for reviewing supplier and product-line commitments.

The takeaway

The sector is expanding, and the leaders are pulling ahead through product adoption rather than price alone. Operators should track the next Sonova and Demant guidance updates as a read on whether the 3% to 5% market growth forecast holds through the fiscal year.

Further reading

For broader context on how medical-device makers are building growth around new technology, see the Healthcare section.